Colostrum from MERS-CoV seropositive camels for MERS prophylaxis and SARS-CoV-2 infection, a placebo controlled randomized trial.

ABSTRACT: COVID-19 pandemic is currently relatively controlled, mainly due to effective vaccines. Preparedness for future outbreaks should include means for reducing transmission of SARS-CoV-2 and other coronaviruses like MERS-CoV. Approximately 72% of camels in Israel are seropositive for MERS-CoV and may exhibit cross-reactivity with serologically related SARS-CoV-2, suggesting therapeutic possibilities.

Aims

To investigate the potential of camel-derived anti-MERS-CoV antibodies from camels colostrum for mucosal use in humans, as MERS-CoV prophylaxis and to control COVID-19 progression and infectivity.

Methods

Using ELISA assay, we screened serum and colostrum of MERS-CoV seropositive camels for MERS-CoV antibody titers and neutralization potency and for cross-reactivity with SARS-Co

SUBMITTER: Masika H 

PROVIDER: S-EPMC12647693 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature